Romanian Medical Journal Logo
  • Home
  • Aims & Scope
  • Standards
    • Editorial policies
    • Instructions for authors
    • Peer review process
    • Guidelines for Reviewers
    • Ethics and Malpractice policies
    • Official Journal’s protocols & statements
    • Open Access
  • Editorial Council
  • Peer Review Council
  • EMC | CME
  • How to
  • SUBSCRIBE
  • Menu

Arhiva autor

  • About
  • Latest Posts

M. Cojocaru

Latest posts by M. Cojocaru (see all)

  • GENETIC RISK FACTORS ASSOCIATED WITH ANTIPHOSPHOLIPID SYNDROME - 05/10/2015
  • THE ROLE OF GENETIC FACTORS IN SPONDYLOARTHROPATIES - 02/10/2015

Articole semnate de acelasi autor in Revista Medicala Romana:

GENETIC RISK FACTORS ASSOCIATED WITH ANTIPHOSPHOLIPID SYNDROME

SELECT ISSUE

REVISTA MEDICALA ROMANA - Romanian Medical Journal, Vol. LXI, Nr. 2, An 2014
ISSN 1220-5478  |  e-ISSN 2069-606X
ISSN-L 1220-5478
DOI: 10.37897/RMJ

Indexed

DOI - Crossref
Similarity Check by iThenticate, worldwide No 1 professional plagiarism checking system
DOAJ
Ebsco Host - Medline
Google Academic
Semantic Scholar

HIGHLIGHTS

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

The published medical research literature is a global public good. Medical journal editors have a social responsibility to promote global health by publishing, whenever possible, research that furthers health worldwide.

GENETIC RISK FACTORS ASSOCIATED WITH ANTIPHOSPHOLIPID SYNDROME

M. Cojocaru and Bogdan Chicos

ABSTRACT

Antiphospholipid syndrome (APS) is characterized by venous or arterial thromboses, fetal losses and thrombocytopenia, in the presence of antiphospholipid antibodies (aPL), namely lupus anticoagulant (LA), anticardiolipin antibodies (aCL) or antibodies directed to various proteins, mainly beta2-glycoprotein 1 (β2-GP1), or in the presence of all three. It is possible that some people with APS have a genetic predisposition for developing this syndrome. Genetic susceptibility related to aPL and APS has been extensively examined during recent years. It is becoming increasingly clear that interactions between more than one genetic abnormality or between a genetic factor and environment components determine whether and when an individual will suffer from venous thrombosis. Given the fact that APS is characterized mainly by the presence of thromboembolic events, it seems perfectly plausible that several genetic factors may also be involved in its pathophysiology. Despite the strong association between aPL and thrombosis, their pathogenic role in the development of thrombosis has not been fully elucidated. This review focuses on some of the genetic risk factors associated with APS.

Keywords: genetics, antiphospholipid antibody, antiphospholipid syndrome

Full text | PDF

M. Cojocaru

THE ROLE OF GENETIC FACTORS IN SPONDYLOARTHROPATIES

SELECT ISSUE

REVISTA MEDICALA ROMANA - Romanian Medical Journal, Vol. LXI, Nr. 3, An 2014
ISSN 1220-5478  |  e-ISSN 2069-606X
ISSN-L 1220-5478
DOI: 10.37897/RMJ

Indexed

DOI - Crossref
Similarity Check by iThenticate, worldwide No 1 professional plagiarism checking system
DOAJ
Ebsco Host - Medline
Google Academic
Semantic Scholar

HIGHLIGHTS

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

The published medical research literature is a global public good. Medical journal editors have a social responsibility to promote global health by publishing, whenever possible, research that furthers health worldwide.

THE ROLE OF GENETIC FACTORS IN SPONDYLOARTHROPATIES

M. Cojocaru, Inimioara Mihaela Cojocaru and Bogdan Chicos

ABSTRACT
The spondyloarthropaties (SpAs) are chronic inflammatory diseases that involve the sacroiliac joints, axial skeleton, and, to a lesser degree, peripheral joints and certain extra-articular organs, including the eyes, skin, and cardiovascular system. Current research has demonstrated that genetics play an integral role in the development of SpAs. Genome screens have identified regions that may contain susceptibility genes for SpAs. The spondyloarthropaties are associated strongly with HLA-B27, an HLA class-I gene. Several genotypic subtypes of HLA-B27 are associated with the SpAs, with HLA-B*2705 having the strongest association. HLA-B*2702, *2703, *2704, and *2707 are also associated with ankylosing spondylitis (AS). HLA-B27-restricted CD8+ (cytotoxic) T cells may play an important role in bacterial-related SpAs such as reactive arthritis. It has been shown that the presence of the genetic marker HLA-B27 increases the likelihood of developing AS. HLA-B27 testing is of limited value. It is important to note that being HLA-B27 positive does not mean that someone will get ankylosing spondylitis (AS) nor does the gene appear in all those who have AS. The pathogenesis of SpAs is linked to a genetic predisposition (essentially HLA-B27). This article reviews the literature concerning the genetics in the most common SpAs.

Keywords: genetic disorders, spondyloarthropathies

Full text | PDF

M. Cojocaru


SEARCH

STANDARDE

  • Instructions for AUTHORS
  • Peer review process

Submit article

Submit your article to the journal by using the form here:

Submit

Subscriptions

To receive the Ro Medical Journal click here:

SUBSCRIBE
Publicare
Abonare

plic-maileditor@rmj.com.ro

Subscribe to the Newsletter

Articles from the journal are licensed under a 
Creative Commons Attribution 4.0 International License

 Terms & Conditions

Open Access Statement

Publisher : AMALTEA Medical Publishing House

The intended audience of the site content is professionals from the medical and pharmaceutical community.
This site does not collect any personal data nor does it use cookies that might obtain such data from your browser. [ info ]
Agree
Privacy & Cookies Policy

Necessary Always Enabled

Non-necessary

Contact

Submit ARTICLE
E-mail: editor@rmj.com.ro  |  Mobile: +4 0742.155.512, M-F 09.00-18.00 EET

SUBSCRIPTIONS
E-mail: info@amaltea.ro |  Mobile: +4 0742.155.511, M-F 09.00-18.00 EET